The Pharmaceutical Benefits Scheme (PBS) spends over A$9 billion a year subsidising a wide range of drugs to ensure affordability for all Australians. But when it comes to rare cancers – such as bone and soft tissue tumours called sarcomas – the scheme falls short. This happens for a number of reasons. The main one ...
Unfair if rare: should the PBS change the way it lists cancer drugs?
By Ian Olver
16 May 2016